CLINICAL EVALUATION OF THE THERAPEUTIC EFFICACY OF SARVAKALPAGHANA VATI AND TOTALA HIMA IN CHRONIC HEPATITIS B

Patanjali Ayurveda College0 个研究点目标入组 50 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Patients irrespective of sex, religion, occupation and chronicity will be selected.
•2. Patients with two times higher ALT levels than the upper limit of normal value will be selected.
•3. Patients with symptoms and signs of hepatitis B, abnormal liver functions and diagnosed cases of Chronic Hepatitis B infection will be registered.

•1. Patients aged >65 years or <18 years will be excluded.
•2. Pregnant or lactating women will be excluded.
•3. Patients who had hepatitis C or other hepatic viral infection, autoimmune hepatitis and drug-induced hepatitis or alcoholic hepatitis will be excluded.
•4. Patients with severe complications of the cardiovascular, renal or hematopoietic systems and mental diseases will be excluded.
•5. Patients will be excluded having decompensated liver disease.
•6. Patients with prolonged or a history of ascites, developed hepato-cellular carcinoma, hepatic encephalopathy, variceal bleeding will be excluded.
•7. Patients with a history of using IFN or antiviral agents or corticosteroids or immunosuppressive drugs will also be excluded.

发起方

Patanjali Ayurveda College